toxylact: a02ab01 aluminium hydroxide
The first professional lActological database in the word
Aluminium hydroxide (ATC A02AB01) is generally considered compatible with breastfeeding when used short term and at usual antacid doses, because systemic absorption is very low and transfer into human milk is minimal.
Aluminium hydroxide and lactation: overview
Aluminium hydroxide is an inorganic salt widely used as an antacid to relieve heartburn, acid indigestion and symptoms of gastroesophageal reflux. After oral administration most of the aluminium salt remains in the gastrointestinal tract and is excreted in the feces, with less than 1% absorbed into the systemic circulation.
Because maternal systemic exposure is low and the compound is poorly absorbed orally, the amount that can reach breast milk and then be absorbed by the infant is expected to be very small. On this basis, expert reviewers and clinical guidelines consider aluminium‑containing antacids to be low risk and generally acceptable during breastfeeding.
Transfer into breast milk
Available data indicate that aluminium compounds do not significantly concentrate in breast milk. Trace amounts of aluminium may be detectable in human milk, but current evidence has not shown an increase in milk aluminium levels in mothers exposed to common aluminium sources, such as topical products or antacids, compared with controls.
Moreover, aluminium and magnesium are naturally present in breast milk and infant foods, and their oral bioavailability in the infant is low, further limiting systemic exposure. The general principles governing drug passage into milk (molecular size, ionization, protein binding and oral bioavailability) predict a low milk transfer and low infant absorption for aluminium hydroxide.
Effects on the breastfed infant
No adverse effects clearly attributable to maternal use of aluminium hydroxide antacids have been reported in breastfed infants at usual therapeutic doses. Authoritative sources, including WHO-based lists and independent lactation reference databases, classify aluminium hydroxide–containing antacids as compatible with breastfeeding, with at most a mild theoretical risk.
In healthy term infants, the very small oral aluminium load from maternal use is unlikely to approach doses associated with toxicity, which in clinical practice have been observed mainly in patients with renal failure receiving aluminium-containing phosphate binders. As a precaution, clinicians often advise using the lowest effective dose for the shortest necessary duration and monitoring the infant for non‑specific gastrointestinal symptoms such as changes in stool pattern or feeding behavior.
Maternal safety and special populations
In the breastfeeding mother, aluminium hydroxide is usually well tolerated when used short term as an antacid, although it can cause constipation, reduced appetite, or, with prolonged high‑dose use, disturbances in phosphate balance. Serious toxic effects such as osteomalacia or encephalopathy have been described mainly in the context of chronic use as a phosphate binder in patients with significant renal impairment and are unlikely at standard over‑the‑counter antacid doses in women with normal kidney function.
However, in mothers with chronic kidney disease or those requiring long‑term high‑dose aluminium-containing preparations, cumulative aluminium exposure may increase and more cautious risk–benefit assessment is warranted. In such situations, considering alternative non‑aluminium antacids or acid‑suppressing therapies with more lactation data may be reasonable, under specialist supervision.
Practical toxiclactology recommendations
From a toxiclactology perspective, occasional or short‑term use of aluminium hydroxide antacids at recommended doses is compatible with breastfeeding and does not justify interruption of lactation. Mothers should be advised to avoid chronic or excessive dosing beyond the product’s instructions, especially if they have renal impairment or are simultaneously exposed to other aluminium sources.
If prolonged therapy is necessary, it is prudent to re‑evaluate the indication, optimize non‑pharmacological reflux measures, and, where appropriate, consider agents with extensive breastfeeding safety data (such as certain H2‑receptor antagonists) while monitoring the infant’s growth and development. When counselling families, it is helpful to emphasize that the benefits of continued breastfeeding, combined with the low predicted infant exposure to aluminium hydroxide, strongly favor continuation of breastfeeding in most clinical scenarios.
